Nuclear Survivin Expression Predicts Poorer Prognosis in Glioblastoma

Overview

Journal J Neurooncol

Publisher Springer

Date 2008 Oct 28

PMID 18953492

Citations 35

Authors

Katsuyuki Shirai

Yoshiyuki Suzuki

Kuniyuki Oka

Shin-Ei Noda

Hiroyuki Katoh

Yoshihiko Suzuki

Jun Itoh

Hideaki Itoh

Shogo Ishiuchi

Hideyuki Sakurai

Masatoshi Hasegawa

Takashi Nakano

Affiliations

Soon will be listed here.

Abstract

Survivin is a member of the inhibitor of apoptosis family, and is expressed in various malignant tumors. Survivin overexpression has been reported to be a poorer prognostic factor in various malignancies. However, the prognostic value of survivin expression in patients with glioblastoma is still controversial. Therefore, in this study the role of survivin as a predictor for survival was investigated in patients with glioblastoma. Tissue specimens were obtained from 66 patients with glioblastoma treated with radiotherapy. Survivin expression was detected by an immunohistochemical method. Nuclear and cytoplasm survivin scores were defined by using the cell positivity and staining intensity. The scores were defined as follows, 0 (no staining), 1 (less than 50% of cell positivity and any staining), 2 (more than 50% of cell positivity and weak to moderate intensity) and 3 (more than 50% of cell positivity and strong intensity). The correlation between survivin scores and the overall survival rate was evaluated. Nuclear and cytoplasm survivin staining were noted in 47 and 58 patients, respectively. The number of patients with nuclear survivin score of 0, 1, 2 and 3, were 19 (28.8%), 26 (39.4%), 9 (13.6%) and 12 (18.2%), respectively. The 3-year overall survival rate of the nuclear survivin score 3 was 0%, significantly lower than the 11.6% of the nuclear survivin score </=2 (P = 0.0003). Cytoplasm survivin score did not correlate with the prognosis. Nuclear survivin expression may be a useful biomarker for predicting prognosis in patients with glioblastoma.

Citing Articles

Survivin as a Therapeutic Target for the Treatment of Human Cancer.

Wang Q, Greene M Cancers (Basel). 2024; 16(9).

PMID: 38730657 PMC: 11083197. DOI: 10.3390/cancers16091705.

The genotypic and phenotypic impact of hypoxia microenvironment on glioblastoma cell lines.

Wanjiku Macharia L, Muriithi W, Pilotto Heming C, Nyaga D, Aran V, Mureithi M BMC Cancer. 2021; 21(1):1248.

PMID: 34798868 PMC: 8605580. DOI: 10.1186/s12885-021-08978-z.

Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination.

Reich T, Schwarzenbach C, Vilar J, Unger S, Muhlhausler F, Nikolova T Cell Mol Life Sci. 2021; 78(14):5587-5604.

PMID: 34100981 PMC: 8257519. DOI: 10.1007/s00018-021-03864-0.

Cytotoxic Effects of Arsenite in Combination With Gamabufotalin Against Human Glioblastoma Cell Lines.

Yuan B, Xu K, Shimada R, Li J, Hayashi H, Okazaki M Front Oncol. 2021; 11:628914.

PMID: 33796463 PMC: 8009626. DOI: 10.3389/fonc.2021.628914.

OSgbm: An Online Consensus Survival Analysis Web Server for Glioblastoma.

Dong H, Wang Q, Li N, Lv J, Ge L, Yang M Front Genet. 2020; 10:1378.

PMID: 32153627 PMC: 7046682. DOI: 10.3389/fgene.2019.01378.

References

Das A, Tan W, Teo J, Smith D . Expression of survivin in primary glioblastomas. J Cancer Res Clin Oncol. 2002; 128(6):302-6. DOI: 10.1007/s00432-002-0343-4. View

OConnor D, Wall N, Porter A, Altieri D . A p34(cdc2) survival checkpoint in cancer. Cancer Cell. 2002; 2(1):43-54. DOI: 10.1016/s1535-6108(02)00084-3. View

Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer K . Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol. 2003; 29(4):379-82. DOI: 10.1053/ejso.2002.1415. View

Span P, Sweep F, Wiegerinck E, Tjan-Heijnen V, Manders P, Beex L . Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem. 2004; 50(11):1986-93. DOI: 10.1373/clinchem.2004.039149. View

Mahotka C, Wenzel M, Springer E, Gabbert H, Gerharz C . Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 2000; 59(24):6097-102. View

Uematsu M, Ohsawa I, Aokage T, Nishimaki K, Matsumoto K, Takahashi H . Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol. 2005; 72(3):231-8. DOI: 10.1007/s11060-004-2353-3. View

Sarela A, Macadam R, Farmery S, Markham A, Guillou P . Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut. 2000; 46(5):645-50. PMC: 1727921. DOI: 10.1136/gut.46.5.645. View

Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D . Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery. 2004; 136(2):443-8. DOI: 10.1016/j.surg.2004.05.023. View

Shariat S, Lotan Y, Saboorian H, Khoddami S, Roehrborn C, Slawin K . Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer. 2004; 100(4):751-7. DOI: 10.1002/cncr.20039. View

10.

Chakravarti A, Zhai G, Zhang M, Malhotra R, Latham D, Delaney M . Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene. 2004; 23(45):7494-506. DOI: 10.1038/sj.onc.1208049. View

11.

Suzuki Y, Oka K, Yoshida D, Shirai K, Ohno T, Kato S . Correlation between survivin expression and locoregional control in cervical squamous cell carcinomas treated with radiation therapy. Gynecol Oncol. 2006; 104(3):642-6. DOI: 10.1016/j.ygyno.2006.10.005. View

12.

Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M . Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology. 2000; 31(5):1080-5. DOI: 10.1053/he.2000.6496. View

13.

Islam A, Kageyama H, Hashizume K, Kaneko Y, Nakagawara A . Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-beta/2B. Med Pediatr Oncol. 2000; 35(6):550-3. DOI: 10.1002/1096-911x(20001201)35:6<550::aid-mpo12>3.0.co;2-y. View

14.

Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, Heine B, STEIN H, Hopfner M . Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer. 2003; 88(1):115-9. PMC: 2376783. DOI: 10.1038/sj.bjc.6600696. View

15.

Yang L, Cao Z, Yan H, Wood W . Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res. 2003; 63(20):6815-24. View

16.

Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M . Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett. 2001; 163(1):109-16. DOI: 10.1016/s0304-3835(00)00677-7. View

17.

Chakravarti A, Noll E, Black P, Finkelstein D, Finkelstein D, Dyson N . Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol. 2002; 20(4):1063-8. DOI: 10.1200/JCO.2002.20.4.1063. View

18.

Mahotka C, Liebmann J, Wenzel M, Suschek C, Schmitt M, Gabbert H . Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ. 2002; 9(12):1334-42. DOI: 10.1038/sj.cdd.4401091. View

19.

Tamm I, Wang Y, Sausville E, Scudiero D, Vigna N, Oltersdorf T . IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998; 58(23):5315-20. View

20.

Preusser M, Gelpi E, Matej R, Marosi C, Dieckmann K, Rossler K . No prognostic impact of survivin expression in glioblastoma. Acta Neuropathol. 2005; 109(5):534-8. DOI: 10.1007/s00401-005-0992-x. View